Study Results Published Showing Advantages with Revlimid in Newly Diagnosed Myeloma
The New England Journal of Medicine published a study this week showing that Revlimid (lenalidomide) plus low-dose dexamethasone improves survival and other measures of efficacy compared to MPT (melphalan, prednisone, and thalidomide) in newly diagnosed multiple myeloma patients who are not eligible for a stem cell transplant. The study also showed that continuing use of Revlimid-dexamethasone instead of stopping after a fixed number of treatments provided further advantages in multiple measures
Source: International Myeloma Foundation - Category: Hematology Source Type: news
More News: Dexamethasone | Hematology | Myeloma | Prednisone | Revlimid | Stem Cell Therapy | Stem Cells | Study | Transplants